Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency as Assessed Using an Integrated Genomic Signature

Next Previous
Search
Trial Profile

Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency as Assessed Using an Integrated Genomic Signature

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Dec 2023 Status changed from recruiting to discontinued (Withdrawal of funding).
    • 28 Nov 2022 Planned initiation date changed from 25 Nov 2022 to 28 Dec 2022.
    • 25 Oct 2022 Planned initiation date changed from 23 Oct 2022 to 25 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top